GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MediClin AG (XTER:MED) » Definitions » EV-to-EBITDA

MediClin AG (XTER:MED) EV-to-EBITDA : 4.92 (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is MediClin AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MediClin AG's enterprise value is €498.5 Mil. MediClin AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €101.3 Mil. Therefore, MediClin AG's EV-to-EBITDA for today is 4.92.

The historical rank and industry rank for MediClin AG's EV-to-EBITDA or its related term are showing as below:

XTER:MED' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.33   Med: 7.01   Max: 15
Current: 4.92

During the past 13 years, the highest EV-to-EBITDA of MediClin AG was 15.00. The lowest was 4.33. And the median was 7.01.

XTER:MED's EV-to-EBITDA is ranked better than
87.83% of 460 companies
in the Healthcare Providers & Services industry
Industry Median: 13.18 vs XTER:MED: 4.92

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), MediClin AG's stock price is €2.82. MediClin AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.230. Therefore, MediClin AG's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


MediClin AG EV-to-EBITDA Historical Data

The historical data trend for MediClin AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediClin AG EV-to-EBITDA Chart

MediClin AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.67 7.35 5.93 6.38 4.89

MediClin AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.38 6.34 6.15 5.20 4.89

Competitive Comparison of MediClin AG's EV-to-EBITDA

For the Medical Care Facilities subindustry, MediClin AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediClin AG's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MediClin AG's EV-to-EBITDA falls into.



MediClin AG EV-to-EBITDA Calculation

MediClin AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=498.489/101.264
=4.92

MediClin AG's current Enterprise Value is €498.5 Mil.
MediClin AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €101.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediClin AG  (XTER:MED) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MediClin AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.82/-0.230
=At Loss

MediClin AG's share price for today is €2.82.
MediClin AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.230.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


MediClin AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MediClin AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MediClin AG (XTER:MED) Business Description

Traded in Other Exchanges
Address
Okenstrasse 27, Offenburg, DEU, 77652
MediClin AG is a company engaged in operating hospitals. It is focused on providing services in the areas of neurosciences and psychological sciences as well as orthopedics in Germany. The hospitals are acute-care hospitals providing basic, standard, and specialized care, as well as specialist clinics for medical rehabilitation. The operating segments of the group are Post-acute, Acute and Other activities. It generates majority of the revenue from the Post-acute segment in which the firm offers services in the fields of subsequent nursing treatment and curative treatment. Subsequent nursing treatment starts after acute care treatment and includes all medical measures required to facilitate the healing process and return the patient to a functioning state.